Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Virâs scale and scope, together with leading scientific and management expertise, allow it to perform significant internal research and development, in-license or acquire innovative technology platforms and assets, and fund targeted academic research. Source
No articles found.
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
Inogenâs mission to improve the quality of life of supplemental oxygen users beg...
Inogenâs mission to improve the quality of li...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...
Arrowhead Pharmaceuticals develops medicines th...
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innovivaâs portf...
Innoviva, Inc. (NASDAQ: INVA) is focused on roy...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.